Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Seite 1 von 43 Ergebnisse
Derivatives used in the treatment of muscle atrophy
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
DESCRIPTION OF THE INVENTION
This invention relates to derivatives useful for the treatment of diseases related to muscle atrophy.
FIELD OF THE INVENTION
Today there is a clear lack of new treatments to delay the onset and progression of age-related disorders and diseases that are accompanied by a
Medicament for atrophy treatment or increasing cell growth
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The present invention relates to the field of drugs for regenerative treatments, in particular for regeneration of muscle cells and mitigation of programmed cell death in human cells of various origins.
BACKGROUND
Predominant diseases characterized by a lack of regeneration of
8-(biaryl)quinoline PDE4 inhibitors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to compounds that are substituted 8-(biaryl)quinolines. In particular, this invention is directed to substituted 8-(biaryl)quinolines which are phosphodiesterase-4 inhibitors wherein the biaryl group at the
2-Aminoquinoline compounds
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
Obesity, defined as excess adiposity for a given body size, results from a chronic imbalance between energy intake and energy expenditure. Body mass index (BMI, kg/m.sup.2) is an accepted clinical estimate of being overweight (BMI 25 to 30) and of obesity (BMI>30). A
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamide heteroarly hydroxamic acids as matrix metalloproteinase and TACE inhibitors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of .beta.-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Melanocortin receptor ligands
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The present invention relates to new melanocortin receptor ligands. These ligands are cyclic peptide analogs that preferably exhibit selectivity for the MC-4 and/or the MC-3 receptors relative to the other melanocortin receptors (in particular the MC-1 receptor).
BACKGROUND OF
Thiazole derivatives
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The subject invention relates to thiazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present
Imidazole derivatives
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The subject invention relates to imidazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present
Imidazole derivatives
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The subject invention relates to imidazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present
PARP inhibitors
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose) polymerase ["poly(ADP-ribose) polymerase" or "PARP", which is also sometimes called "PARS" for poly(ADP-ribose) synthetase]. More particularly, the invention relates to
Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird
- Arbeitet in 55 Sprachen
- Von der Wissenschaft unterstützte Kräuterkuren
- Kräutererkennung durch Bild
- Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
- Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
- Suchen Sie nach Heilkräutern nach ihrer Wirkung
- Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden
Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen
